title: Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis.
abstract: We conducted a pooled analysis of clinical trials comparing intravenous Fenoldopam (FP) with Saline/Placebo/N-acetyl cysteine (NAC) for the prevention of contrast-induced nephropathy (CIN). Five studies were eligible. Quantitative analyses were done with Review Manager (RevMan version 5.2.). A total of 85 out of 353 patients in Fenoldopam group while 73 among 366 in the control group were affected due to CIN. The risk ratio for the development of CIN in the Fenoldopam group was 1.19 compared to the control group. This was not statistically significant. Fenoldopam is no better than Placebo/Saline or NAC in preventing CIN, but more studies are required.
authors.affiliation: Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI. Electronic address: Muhammad_naeem@brown.edu.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Naeem
authors.affiliation: Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI.
authors.forename: Gregory E
authors.initials: GE
authors.lastname: McEnteggart
authors.affiliation: Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI.
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Murphy
authors.affiliation: Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI.
authors.forename: Ethan
authors.initials: E
authors.lastname: Prince
authors.affiliation: Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI.
authors.forename: Sun
authors.initials: S
authors.lastname: Ahn
authors.affiliation: Vascular Disease Research Center, Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI.
authors.forename: Gregory
authors.initials: G
authors.lastname: Soares
mesh_terms: D003287:Contrast Media / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D018818:Fenoldopam / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D003287:Contrast Media; D018491:Dopamine Agonists; D018818:Fenoldopam
keywords: Contrast nephropathy; Corlopam; Fenoldopam; N-acetylcysteine